Antipsychotics

People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.

A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.

New research examines service user attitudes on discontinuing and reducing antipsychotic drugs.

Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.

In JAMA psychiatry, researchers outline new theories connecting antipsychotic use in people with schizophrenia and increased dementia risk.

Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.

In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.

Researchers highlight how systematic reviews are compromised by pharmaceutical industry ties by exposing a study of injectable antipsychotics.

The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.

Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.

Peter Lehmann reviews the contribution of antipsychotics to suicide and depression in schizophrenia in the current International Journal of Psychotherapy.  Publications about the intrinsic effects of...

This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.

A study, recently published in Psychological Medicine, examined the cognitive functioning of individuals with schizophrenia who discontinued antipsychotics, and those who maintained their antipsychotic...

The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.

A recent RCT showed that vitamin B6 is as effective as propranolol for the treatment of akathisia.

A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.

The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.

Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.

This guide, by psychiatrists Volkmar Aderhold and Peter Stastny, provides a comprehensive review of antipsychotics and an evidence-based rationale for avoiding their use in first-episode psychosis, and for minimizing their long-term use.

New research reveals that patients are often not given fully informed consent before being prescribed antipsychotics.

The researchers found that while antipsychotic drugs may be slightly more effective than alternative antidepressants, they come with a much higher side effect burden.

Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.

Patients who recover from a single episode of psychosis are often prescribed antipsychotics long-term, despite a lack of evidence for this practice

Withholding antipsychotics may be beneficial for memory, the researchers write.

People who take antipsychotic medications experience many side effects which have "major disruptive impact on their lives," according to research in the Journal of Mental Health Nursing.